NovoCure

NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Company Growth (employees)
Type
Public
HQ
Jersey, JE
Founded
2000
Size (employees)
460 (est)
NovoCure was founded in 2000 and is headquartered in Jersey, JE

Key People/Management at NovoCure

Bill Burke

Bill Burke

Global Head HR
Laura Benson

Laura Benson

Vice President Medical Affairs
Moshe  Giladi

Moshe Giladi

Head of preclinical research

NovoCure Office Locations

NovoCure has offices in Jersey, Chiyoda-ku, Root, Portsmouth and in 38 other locations
Jersey, JE (HQ)
Le Masurier House, La Rue Le Masurier
Haifa, IL
Shoshanat Ha'Karmel St
Portsmouth, US
195 Commerce Way
Root, CH
D4 Pk., 6039 Root
Chiyoda-ku, JP
1 Chome-9 Marunouchi, Tōkyō-to 100-6736
Show all (42)

NovoCure Financials and Metrics

NovoCure Financials

USD

Market capitalization (31-Oct-2017)

1.9 b

Closing share price (31-Oct-2017)

20.4
NovoCure's current market capitalization is $1.9 b.
Show all financial metrics

NovoCure Market Value History

NovoCure's Web-traffic and Trends

NovoCure Online and Social Media Presence

NovoCure Company Life and Culture

You may also be interested in